We intend to pursue a sustained rate of growth over the next few years. Our deposits of growth are those of the strong demand of the Algerian market and potential of development that it offers but also those of the rationalization of our operational costs by the specialization that we put in place in the scale of our Organization. In the long term, we also look forward to broaden the horizon of our markets in the direction of the African countries; as well as to gain foothold in the European market.

Our main assets reside first in the quality of our production’s tool and our ability to manufacture and placing on the market of generic drugs prepared and designed in our laboratory for research and development, as well as many of the products that we entrust of major international laboratories, are in the framework of license contracts or sub-contracting. Our commitment to quality, which has just be devoted in 2015 by the certification to the GMP issued by the MSNA (French National Agency of safety of the drug and health products) to our production site of Oued SMAR (Algiers), will be relentlessly pursued through our ambitious investment program.

They also reside in the quality and density of a network of high-performance distribution covering the entire Algerian territory and that we put at the service of the promotion of our own products as well as those of our many partners. We remain particularly attentive to the dynamics of scientific innovation and technological progress that animates the pharmaceutical scene on a global scale. It is the very basis of many fruitful partnerships as we have with the big pharmaceutical laboratories and who help us to provide therapeutic solutions covering the bulk of pathologies

Our ambition is to continue permanently to propose the most innovative treatments and to make them more available and accessible for Algerians patients. We will continue, therefore, the important efforts that we have undertaken throughout the past twenty years in terms of close relations with the national medical community and with the health authorities, as well as in terms of the popularization of scientific information around the drug and the quality of care and treatment to give Algerians patients